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Abstract
Background There is an increasing interest for combined
nutraceuticals that can act on several points of lipid and
glucose metabolism with preventive purposes. However,
the simple assemblage of nutraceuticals with potentially
additive mechanism of action need to be clinically tested.
Methods To assess the effects of a combination of
nutraceuticals based on artichoke, red yeast rice, banaba,
and coenzyme Q10, we performed a double bind, cross-
over designed trial versus placebo in 30 adults with LDL
cholesterol suboptimal in primary prevention of cardio-
vascular disease. After a period of 3 weeks of dietary
habits correction, patients began a period of 6 weeks of
treatment with nutraceutical or placebo, followed by
2 weeks of washout and finally 6 weeks in cross-over. Data
related to lipid pattern, insulin resistance, renal function,
liver and CPK have been obtained at each visit.
Results In particular, the after the nutraceutical treatment
the enrolled patients experienced a significant improve-
ment in total cholesterol (-13.6 %), LDL-C (-18.2 %),
non-HDL-C (-15 %), glutamic oxaloacetic transaminase
(-10 %), glutamate-pyruvate transaminase (-30.9 %),
and hs-CRP (-18.2 %) versus placebo. No changes have
been observed in the other investigated parameters in both
groups.
Conclusions The tested combination of nutraceuticals has
shown clinical efficacy in the reduction of total cholesterol,
non-HDL, LDL and triglycerides, while improving the
level of liver transaminases and high sensitivity C-reactive
protein. Further confirmation are needed to verify these
observations on the middle and long term with a larger
number of subjects.
Keywords Nutraceuticals  Monacolin K  Insulin-
sensitivity  Dyslipidemia  Artichoke  Banaba  Coenzyme
Q10
1 Introduction
Cardiovascular disease is the leading cause of death in the
developed countries. The main risk factors, evaluated by
the INTERHEART case–control study, are dyslipidemia,
smoking, psychosocial factors, diabetes and hypertension
[1]. In particular, dyslipidemia is considered the principle
modifiable risk factor, because of its role in the develop-
ment of atherosclerosis and clinical events [2]. Guidelines
for dyslipidemia management suggest a treatment that
include lifestyle modification and pharmacotherapy based
on identification of groups considered at high, medium or
low risk of major cardiovascular events [3]. Nevertheless,
lifestyle changes are not always sufficient to reach desir-
able cholesterol levels, in particular in high-risk subjects,
but also in low risk patients that have sub-optimal lipid
parameters.
Nutraceuticals are borderline devices between nutrients
and drugs providing a supplementation of particular
nutrients with beneficial effects on health. More than 40
nutraceutical substances have been studied in order to
improve lipid metabolism and some clinical trials demon-
strated a cholesterol lowering activity, an improvement of
glucose metabolism and inflammatory parameters, besides
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a possible positive influence on cardiovascular prognosis
[4]. Among them, red yeast rice, artichoke, banaba and
coenzyme Q10 showed interesting results.
Red yeast rice is a nutraceutical produced by fermenting
white rice with the yeast, Monascus purpureus. Its content
in monacolins is responsible of its lipid-lowering proper-
ties, by the inhibition of hydroxymethylglutaryl-coenzyme
A reductase, the rate limiting step in cholesterol synthesis.
Many clinical trials have found red yeast rice effective at
improving the lipid profile. It has also been used as an
alternative to drugs in patients with mild to moderate
hypercholesterolemia and in subjects intolerant to statin
therapy due to statin-associated myalgia. Furthermore, a
large randomized controlled study significantly showed
that the intake of red yeast rice improve the risk of major
adverse cardiovascular events and overall survival in
patients following myocardial infarction [5].
The artichoke (Cynara scolymus) inhibits cholesterol
biosynthesis [6] and of low-density lipoprotein (LDL)
oxidation, improving endothelial function [7]. Moreover,
clinical studies have shown also choleretic, hepatoprotec-
tive [8] and glucose lowering activity [9].
Lagerstroemia speciosa, commonly known as banaba, is a
tropical plant found in many parts of South-East Asia. In the
Philippines, the dried and shredded banaba leaves are used as
a treatment for diabetes and kidney disease. Many studies
in vivo and in vitro confirmed the antidiabetic activity of
banaba, due to both corosolic acid as well as ellagitannins
[10]. The mechanisms of action involved include enhanced
cellular uptake of glucose, impaired hydrolysis of sucrose
and starches, decreased gluconeogenesis and the regulation
of lipid metabolism. These activities can be mediated by
peroxisome proliferator-activated receptor (PPAR), mitogen-
activated protein kinase (MAP K), NF-jB and other signal
transduction factors. The supplementation with banaba has
demonstrated to be safe and well tolerated in clinical trials
[11]. Moreover, its action on both lipid and glucose meta-
bolism make banaba a potential useful tool also in the
management of metabolic syndrome [12].
Coenzyme Q10 (CoQ10) is a naturally occurring com-
ponent present in living cells. The potential use of coen-
zyme Q10 supplements may help prevent or treat some
pathologies, in particular cardiovascular diseases, high
blood pressure, obesity and diabetes. It acts as an essential
cofactor for ATP production and to perform important
antioxidant activities in the body [13]. Moreover, it inhibits
LDL oxidation and thus the progression of atherosclerosis.
It decreases pro-inflammatory cytokines and decreases
blood viscosity, which could be useful in subjects with
heart failure and coronary artery disease [14]. This is
important because low-grade inflammation and oxidative
stress are the key factors in the pathogenesis and devel-
opment of atherosclerosis and its complications [15].
The association of more nutraceuticals has demonstrated
a synergistic effects, in particular in patients that present
two or more risk factors for cardiovascular diseases
[16, 17].
This clinical trial has the aim to test the effectiveness
and safety of a combination of red yeast rice, artichoke,
banaba and coenzyme Q10 on glucose metabolism, lipid
pattern and inflammatory parameters in hypercholes-
terolemic patients.
2 Materials and Methods
2.1 Study Design
This double blind, placebo-controlled, randomized clinical
trial was carried out in 40 moderately hypercholesterolemic
patients with metabolic syndrome, in primary prevention
for cardiovascular diseases, consecutively enrolled in the
ambulatory service of cardiovascular disease prevention in
the Medical and Surgical Sciences Department of the
University of Bologna.
The study was a cross-over designed trial of 18 weeks,
preceded by 3 weeks of diet stabilization in which patients
received standard behavioural and qualitative (not quanti-
tative) dietary suggestions to correct unhealthy habits. In
particular, subjects were instructed to follow a general
indication of a Mediterranean diet, avoiding excessive
intake of dairy products and red meat derived products
during the study, and maintaining overall constant dietary
habits. Individuals were also generically encouraged to
increase their physical activity by walking briskly for
20–30 min, 3–5 times per week, or by cycling.
Inclusion criteria were:
– age between 25 and 75
– LDL-cholesterol (LDL-C) level between 130 and
190 mg/dL
– Body mass index (BMI) value between 25 and
30 kg/m2
– Triglycerides (TG) level between 150 and 400 mg/dL
– Fasting plasma glucose (FPG) level under 125 mg/dL.
– When present, assumption of lipid-lowering or antihy-
pertensive drugs stabilized since at least 6 months.
Exclusion criteria were:
– secondary prevention for cardiovascular diseases
– assumption of antidiabetic drugs
– inconstant or not-stabilized assumption of drugs which
may interfere with lipid or glucose metabolism
– chronic gastrointestinal diseases and assumption of
drugs for their treatment
– known thyroid, liver, renal or muscle diseases
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– known allergy or intolerance to a component of the
tested product
– any medical or surgical condition which could lead to
an inconstant adhesion to the protocol.
The study was fully conducted in accordance with the
Declaration of Helsinki, its protocol was approved by the
Ethical Committee of the University of Bologna, and
informed consent was obtained from all patients before the
inclusion in the study.
2.2 Treatments
After 4 weeks of diet and physical activity stabilization,
patients were allocated to treatment with an indistinguish-
able pill of placebo or with an active product containing
500 mg of artichoke extract, 200 mg of red yeast rice
(corresponding to 10 mg of monacolin K), 75 mg of banaba
extract, 50 mg of coenzyme Q10, 9 mg of vitamin B3,
1.4 mg of vitamin B6, 0.83 mcg of vitamin B12, 110 mcg
of folic acid, kindly offered by Named SpA (Lesmo, Italy).
After 6 weeks of treatment (or placebo), patients were
asked to observe a 2-week washout period, and they were
then assigned to the alternative treatment for a further
period of 6 weeks. Clinical and laboratory data have been
obtained at the baseline, at the end of the first treatment
period, after the washout, and again after the second
treatment period.
Randomization was done assigning an alphabetical code
to each lot code (corresponding to treatment or placebo)
impressed on the pillbox. Codes were then kept in a sealed
envelope, which was not opened until the end of the trial.
Pillboxes were then mixed, and the investigators assigned a
blinded pillbox to each enrolled patient.
Throughout the study, we instructed patients to take the
product first dose on the day after they were given the study
product. At the same time, all unused products were
retrieved to the investigator.
2.3 Assessments
Personal data, CVD history and pharmaceutical anamnesis
of each patient were inquired at the beginning of the trial.
Anthropometrical parameters, such as body weight, waist
circumference and BMI were collected both at the begin-
ning and during the trial, together with hemodynamic and
biochemical parameters. BMI was calculated as weight in
kilograms divided by the square of height in meters.
Hemodynamic parameters were collected measuring
orthostatic and clinostatic systolic and diastolic blood
pressure (mean value of 3 interval measures). Also ortho-
static and clinostatic wrist blood pressure (mean value of 3
interval measures) and cardiac frequency were collected.
All biochemical parameters were obtained after a 12-h
overnight fast. The following parameters were obtained or
calculated through appropriate formulas: total cholesterol
(TC), high-density lipoprotein-cholesterol (HDL-C), TG,
LDL-C, non-HDL cholesterol (non-HDL-C), FPG, fasting
insulin, homeostatic model assessment of insulin resistance
(HOMA-IR), creatinine, serum uric acid (SUA), liver
transaminases [glutamic oxaloacetic transaminase (GOT);
glutamate-pyruvate transaminase (GPT)], gamma glu-
tamyl-transferase (cGT), and hsCRP [18]. All measure-
ments were centrally performed in the laboratory of our
department with standardized methods [19].
HOMA-IR is the simplest and most commonly used
method to estimate insulin resistance. It was calculated as
the product of basal glucose (mmol/L) and fasting insulin
(U/mL) divided by 22.5 [20].
Adherence to behavioural counselling and to treat-
ment/placebo, tolerability, acceptability and compliance
were also assessed.
2.4 Statistical Analyses
Data have been analysed using intention to treat by mean of
the Statistical Package for Social Science (SPSS) 21.0,
version for Windows. Normally distributed baseline char-
acteristics of the population have been compared using
Student’s t test, non-normally distributed parameters using
Mann–Whitney U test. Two-way analyses of variance for
crossover design were used to assess the effect of treatment
during the assumption of placebo or treatment. All data are
expressed as means and standard deviation (SD). To verify
the basic assumptions of crossover design, besides the
evaluation of period effect, the presence of a carryover
effect was excluded. Level of statistical significance was
set on P = 0.05.
3 Results
The main characteristics of the enrolled patients have been
resumed in Table 1.
At the baseline, the two treatment sequence groups were
balanced for all the investigated parameters. All the
patients completed the study and no one experienced
adverse events during the trial.
Compared to baseline values, no change has been
observed after both treatments as it regards Body weight,
body mass index, waist circumference, diastolic blood
pressure (DBP), pulse pressure (PP), heart rate (HR), cre-
atinine and SUA level (Table 2).
On the other hand, significant improvements have been
reported in lipid, hepatic and inflammatory parameters in
the active group versus placebo. In particular, there have
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been a mean reduction of total cholesterol of -34.1 mg/dL
(-56.8; -11.3 mg/dL; P\ 0.001), LDL-cholesterol of
-30.3 mg/dL (-49.7; -7.4; P\ 0.001), non-HDL
cholesterol of -31.2 mg/dL (-45.5; -8.1; P\ 0.001),
GOT of -2.3 U/L (-5.7; -0.9; P\ 0.024), GPT of
-6.8 U/L (-10.4; -1.4; P\ 0.011), hs-CRP of -0.4
(-0.9; -0.1; P\ 0.019).
Fasting plasma glucose and insulin levels also mildly
improved in the nutraceutical group, but the observed
changes did not reach the statistical significance.
4 Discussion
The increase of the average age and the quality of life has
caused a raise of cardiovascular diseases in the developed
countries, that cannot be contained only with an improve-
ment of lifestyle and the use of drugs, either in terms of
costs either of the management of potential side effects
[21]. In fact, even though the improvement in its treatment,
cardiovascular diseases remain the first cause of death in
the developed countries and it is increasingly necessary a
widespread prevention [22]. So, it is important to treat its
principle risk factors, since they reach borderline values.
Considering that patients must be divided into low, med-
ium and high cardiovascular risk, the primary approach for
the first category consists in a change of dietary habits and
physical activity [23]. Nevertheless, the improvement of
lifestyle is often not enough to get the parameters in the
optimal range, while, in these patients, the use of drugs can
be excessive and give avoidable side effects. The use of
nutraceuticals has demonstrated to be a useful tool, because
of its safety, high tolerability and the opportunity to treat
more risk factors with only one poly-pill.
In literature, banaba, red yeast rice, artichoke and
coenzyme Q10 have been tested mainly alone [24–27] or in
association towards only one risk factor. For example,
artichoke leaf extract and red yeast rice have been studied
in their synergic effect on lipid metabolism [28].
In this clinical trial, the lipid-lowering properties of red
yeast rice, the hypoglicemic effects of banaba together with
the choleretic, hepatoprotective and bile-enhancing effects
of artichoke and the antioxidant activity of coenzyme Q10
have been studied together and have demonstrated to be
synergic. The results in fact have shown their effectiveness
on lipid metabolism, hepatic and inflammatory parameters
and the improvement of glucose metabolism in hyperc-
holesterolemic patients. In particular, the after the
nutraceutical treatment the enrolled patients experienced a
significant improvement in TC (-13.6 %), LDL-C
(-18.2 %), non-HDL-C (-15 %), GOT (-10 %), GPT
(-30.9 %), and hs-CRP (-18.2 %). The results are in line
with what expected from previous trials carried out on the
individual components [29, 30], but achieved with a single
administration per day of more nutraceuticals combined in
a tablet. Of particular interest, is the improvement of liver
transaminases, both because usually the increase of
transaminases is a common feature with lipid-lowering
therapy [31], and because high transaminases could be a
marker of liver steatosis, that seems to be per se an
emerging risk factor for cardiovascular disease [32].
Nevertheless, our trial has some limitation. The first one
is the relatively small sample size, partially balanced by the
cross-over design of the trial. The second one is the rela-
tively short duration of the trial, however comparable with
the most part of explorative trials carried out with
metabolically active nutraceuticals. Then, we have not
prescribed a specific diet based on bromatological data, but
we gave only general dietary suggestion finalized at
avoiding dietary excess in order to simulate more strictly a
condition of general practice.
Table 1 Baseline characteristics of the subjects enrolled in the trial
N. 30 Mean SD
Age (years) 52.20 7.0
Weight (kg) 80.6 7.5
Body mass index (kg/m2) 26.7 1.8
Waist circumference (cm) 99.8 7.6
SBP (mmHg) 134.2 8.6
DBP (mmHg) 80.4 3.4
Pulse pressure (mmHg) 54.1 6.3
MAP (mmHg) 97.5 7.5
Heart rate (bpm) 72.4 4.4
FPG (mg/dL) 106.9 4.9
Insulin (lU/mL) 12.5 3.3
HOMA-IR 3.4 0.8
Total cholesterol (mg/dL) 248.7 14.3
LDL-C (mg/dL) 165.2 13.2
Triglycerides (mg/dL) 219.4 17.1
HDL-C (mg/dL) 40.1 2.9
Non HDL-C (mg/dL) 205.8 13.4
GOT (U/L) 22.7 6.7
GPT (U/L) 21.9 6.3
Serum uric acid (mg/dL) 4.3 0.9
Creatinine (mg/dL) 0.9 0.1
hsCRP (mg/dL) 2.2 0.4
SBP systolic blood pressure, DBP diastolic blood pressure, MAP
mean arterial pressure, LDL-C LDL cholesterol, HDL-C HDL
cholesterol, non HDL-C non HDL cholesterol, FPG fasting plasma
glucose, HOMA-IR homeostatic model assessment of insulin resis-
tance, GOT glutamic oxaloacetic transaminase, GPT glutamate-
pyruvate transaminase, hsCRP high sensitivity C-reactive protein
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5 Conclusions
In our clinical trial, the use of combined nutraceuticals has
demonstrated to be well tolerated in hypercholesterolemic
patients and has shown to be effective in the simultaneous
improvement of more risk factors: dyslipidaemia, liver
transaminases and hsCRP. These results have to be con-
firmed in larger and longer trials.
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